Connection
Kalipada Pahan to Neuronal Ceroid-Lipofuscinoses
This is a "connection" page, showing publications Kalipada Pahan has written about Neuronal Ceroid-Lipofuscinoses.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.978 |
|
|
|
-
Kim K, Kleinman HK, Lee HJ, Pahan K. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. 2017 06 17; 12(1):113.
Score: 0.662
-
Ghosh A, Rangasamy SB, Modi KK, Pahan K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
Score: 0.652
-
Ghosh A, Corbett GT, Gonzalez FJ, Pahan K. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
Score: 0.476
-
Chakrabarti S, Chandra S, Roy A, Dasarathi S, Kundu M, Pahan K. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARa: Implications for late-infantile Batten disease therapy. Neurobiol Dis. 2019 07; 127:362-373.
Score: 0.187